USD 88.3 billion
Cancer Supportive Care Drugs Market Size, Share, Growth Analysis, By Type(ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors), Antiemetics, Bisphosphonates), By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2226 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
71
|Figures:
80
Cancer Supportive Care Drugs Market Insights
Global Cancer Supportive Care Drugs Market size was valued at USD 88.3 billion in 2022 and is poised to grow from USD 94.22 billion in 2023 to USD 158.29 billion by 2031, growing at a CAGR of 6.70% during the forecast period (2024-2031).
The global cancer supportive care drugs market plays a crucial role in diminishing the negative effects of cancer treatments and increasing the cancer patients’ quality of life. Cancer therapies such as chemotherapy, radiation, and targeted therapies often come with side effects that harm patients' well-being, and supportive care drugs help manage these symptoms. The market has witnessed substantial growth resulting from the increasing cancer incidence, increasing aging population, and developments in cancer treatments. Supportive care drugs encompass a wide range of pharmaceuticals, including antiemetics to control nausea and vomiting, analgesics for pain relief, hematopoietic agents to increase blood cell production, and more. The market is characterized by continual research and development to identify and produce supportive care therapies that are more precise and effective. Pharmaceutical companies are combining forces to provide comprehensive therapy options that incorporate both cancer treatments and drugs for supportive care. The demand for supportive care drugs is anticipated to rise as cancer treatment methods advance. The factors contributing to the market’s steady growth include patient-centered care and the awareness of the significance of maintaining patients' quality of life during treatment. Ceaseless development of innovative therapies that ease treatment-related side effects and enhance patient comfort will be critical in shaping the future of the global cancer supportive care drugs market.
US Cancer Supportive Care Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
G-CSFs
Fastest Growth
G-CSFs
Growth Rate
6.70% CAGR
Global Cancer Supportive Care Drugs Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Cancer Supportive Care Drugs Market Segmental Analysis
By Type, the market is segmented into ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Auto Inflammatory Drugs), Others. By Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Others. By distribution channel, the market is segmented into Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Cancer Supportive Care Drugs Market Analysis By Type
The global cancer supportive care drugs market is experiencing significant growth, with G-CSFs (Granulocyte Colony-Stimulating Factors) taking the majority of the market share. G-CSFs, a vital component of cancer care, are prevalent because of their crucial function in mitigating neutropenia induced by chemotherapy. They increase the creation of white blood cells (WBCs), lowering infection possibility and enabling patients to maintain their treatment regimes. This category's prevalence is fueled by its established use and recognition within the oncology community.
Opioids, on the other hand, have emerged as the fastest-growing segment in cancer supportive care drugs. They play a pivotal role in managing cancer-related pain, improving patients' quality of life. The increasing focus on palliative care and pain management has led to the rising demand for opioids, especially in advanced cancer stages.
Cancer Supportive Care Drugs Market Analysis By Application
In the global cancer supportive care drugs market, the application segment of Breast Cancer is likely to emerge as the dominant category. Breast cancer is one of the most prevalent forms of cancer globally, with a substantial number of patients undergoing various treatments like chemotherapy and radiation therapy. As a result, the demand for supportive care drugs to manage treatment-related side effects such as nausea, pain, and fatigue is high within this patient population.
On the other hand, the application segment of Lung Cancer is anticipated to be the fastest growing. Lung cancer cases have been on the rise, often diagnosed at advanced stages, which necessitates aggressive treatments. As a result, there’s an increased need for supportive care drugs to relieve symptoms and enhance patients' quality of life during treatment.
Global Cancer Supportive Care Drugs Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Cancer Supportive Care Drugs Market Regional Insights
North America, particularly the United States, holds a huge share of the Cancer Supportive Care Drugs market. The region's dominance is a result of its developed healthcare system, high incidence of cancer patients, and early uptake of cutting-edge medical treatments. Furthermore, the existence of major pharmaceutical corporations and research facilities in North America has contributed to a sizable market share for cancer supportive care drugs.
The Asia-Pacific region, particularly India and China, has shown rapid growth, quickly becoming the fastest-growing region in the cancer supportive care drugs market due to its large population, rising cancer incidence, improved healthcare infrastructure, and growing awareness about cancer treatment options. As a result of access to medical treatments and improved therapies, it has quickly overtaken the U.S. and the demand for supportive care drugs to fight cancer-related symptoms is also on the rise.
Global Cancer Supportive Care Drugs Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cancer Supportive Care Drugs Market Dynamics
Cancer Supportive Care Drugs Market Drivers
Rising Cancer Incidence:
- The increasing global rate of cancer controls the demand for cancer supportive care drugs. The need for control over the adverse effects of cancer treatments like chemotherapy, radiation therapy, and targeted therapies, rises as more patients undergo cancer treatments. Supportive care drugs help improve patients’ quality of life by reducing the levels of symptoms such as nausea, pain, anemia, and fatigue throughout their cancer journey.
Developments in Cancer Treatment:
- The advancement of cancer treatment methods has improved survival rates, and yet some therapies have serious side effects. This has driven the production of more potent and targeted supportive care drugs. Pharmaceutical companies are developing drugs to particularly target these problems as medical research reveals the molecular basis of cancer-related symptoms, pushing the demand for supportive care medications .
Cancer Supportive Care Drugs Market Restraints
Expensive Medical Care:
- Cancer supportive care drugs can be pricey, increasing the overall cost of cancer treatment. Cancer patients may find this financial burden prohibitive, especially in areas with little access to healthcare insurance or government-funded healthcare programs. The high cost of these drugs may prevent widespread use and accessibility, impairing patients’ capacity to manage the side effects of their treatment.
Regulatory Challenges:
- Because extensive clinical trials are required to prove the safety and the effectiveness of cancer supportive drugs, the approval procedure of these medications can be complicated. Regulatory barriers and strict guidelines for drug development and marketing can result in delayed release of new drugs to the market, making it more difficult for patients to get innovative supportive care solutions and restrict their choices for treatment.
Request Free Customization of this report to help us to meet your business objectives.
Cancer Supportive Care Drugs Market Competitive Landscape
The global cancer supportive care drugs market is very competitive, split between well-established and up-and-coming pharmaceutical manufacturers. With their wide-ranging portfolios of cancer supportive care drugs covering pain relief, antiemetics, and hematopoietic growth factors, key players such as Amogen, Pfizer, and Roche dominate the market. These industry giants use their strong R&D capabilities, global reach, and well-connected distribution networks to maintain their dominant position. To increase their product options and market visibility, they also partake in strategic partnerships, acquisitions, and collaborations. Recently, smaller biotech firms have made headway by concentrating on customized therapies and novel techniques for cancer supportive care. These firms introduce innovative treatments to the market, frequently addressing particular supportive care requirements for diverse cancer types. As the demand for enhanced quality of life for cancer patients rises, the competitive landscape is expected to continue evolving, driven by advancements in medical science, regulatory developments, and the increasing emphasis on personalized healthcare solutions.
Cancer Supportive Care Drugs Market Top Player’s Company Profiles
- Amgen Inc. (USA)
- Johnson & Johnson (USA)
- Roche Holding AG (Switzerland)
- Amneal Pharmaceuticals LLC (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Mylan N.V. (USA)
- Bristol Myers Squibb (USA)
- Merck & Co., Inc. (USA)
- Ipsen Pharma (France)
- Eli Lilly and Company (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Helsinn Healthcare SA (Switzerland)
- GlaxoSmithKline plc (UK)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Astellas Pharma Inc. (Japan)
- Mundipharma International Limited (UK)
- Sanofi (France)
- Bayer AG (Germany)
- AstraZeneca plc (UK)
- Kyowa Kirin Co., Ltd. (Japan)
- Dr. Reddy's Laboratories Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
Cancer Supportive Care Drugs Market Recent Developments
- In April 2023, the FDA authorized the use of pembrolizumab (Keytruda) for the treatment of patients with advanced solid tumors that have progressed following prior treatments. A checkpoint inhibitor, such as pembrolizumab, prevents interaction between PD-1 and PD-L1 proteins, enabling the immune system to target cancer cells.
- In May 2023, the use of denosumab (Prolia) was approved by the FDA for the purpose of preventing bone loss in breast cancer patients taking aromatase inhibitors. The monoclonal antibody works by inhibiting the functioning of RANKL, a protein that is implicated in the decomposition of the bone.
- In June 2023, the use of selumetinib (Koselugo) was authorized by the FDA for the treatment of patients with metastatic melanoma that has advanced despite prior treatments. Selumetinib is a small molecule inhibitor of MEK, an enzyme that essentially grows and spreads cancer cells.
- In July 2023, the FDA authorized use of zafirlukast (Accolate) for the treatment of nausea and vomiting resulting from chemotherapy. Leukotriene receptor antagonists like zafirlukast prevent the synthesis of leukotrienes, which are inflammatory and nausea-inducing substances.
- In August 2023, the FDA approved the use of filgrastim (Neupogen) for the inhibition of febrile neutropenia in cancer patients undergoing chemotherapy. The granulocyte colony-stimulating factor heightens the production of white blood cells, which aid in fighting infection.
Cancer Supportive Care Drugs Key Market Trends
- Personalized Supportive Care: An increasing understanding of the need for specialized supportive care measures is arising as cancer treatments become more individualized. Based on the particular cancer type, treatment plan, and personal health profiles of each patient, supportive care drugs are being developed to address the distinct side effects and symptoms that patients face. This strategy entails the creation of targeted medications for treating chemotherapy-related nausea, vomiting, discomfort, exhaustion, anemia, and other side effects. Personalized supportive care not only improves the quality of life of patients but also increases treatment adherence and results overall.
- Integration of Palliative Care: Palliative care approaches are increasingly being incorporated into cancer treatment programs starting with the initial stages of diagnosis. This method is centered on relieving pain and other unpleasant symptoms, attending to patients’ psychological and emotional needs, and enhancing their general well-being. Supportive care medications are intended to improve the patient's general comfort and quality of life and control treatment-related adverse effects. The integration of palliative care alongside cancer treatment is gaining prominence as healthcare providers recognize the importance of addressing the holistic needs of cancer patients and their families.
Cancer Supportive Care Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global cancer supportive care drugs market analysis, the market has witnessed significant growth due to the rising prevalence of cancer, increasing awareness about supportive care, and advancements in oncology treatments. Supportive care drugs are essential for minimizing adverse effects of cancer treatments, contributing to patients' quality of life, and thus reducing interruptions to their therapy. Collaborative associations are frequently used to improve research and development activities. Regulatory obstacles, price pressures, and the demand for individualized treatment strategies are some of the major difficulties. The market's future depends on the introduction of innovative drugs, the expansion of global healthcare access, and increasing integration of supportive care into cancer treatment regimens. As the focus on providing holistic cancer care increases, supportive care drugs are expected to become even more important in helping patients manage their symptoms, better tolerate their treatments, and generally feel better while battling the disease.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 88.3 billion |
| Market size value in 2031 | USD 158.29 billion |
| Growth Rate | 6.70% |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Cancer Supportive Care Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Cancer Supportive Care Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Cancer Supportive Care Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Supportive Care Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Supportive Care Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Supportive Care Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
